# Biotech Daily Digest — 2025-09-22

**29 items from 4 sources**

## Summary by Source

- Endpoints News: 4 items
- Fierce Biotech: 6 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 18 items


## Endpoints News

- **[Avenzo collects another $60M for two small molecules and two ADCs licensed from China](https://endpoints.news/avenzo-collects-another-60m-for-two-small-molecules-and-two-adcs-licensed-from-china/)**  
  _Mon, 22 Sep 2025 13:00:50 +0000_  
  Avenzo Therapeutics, an early adopter of the China-to-US licensing model, has brought in another $60 million for its four investigational cancer treatments.

 With the Series B, the San Diego-based biotech has now raised $446 million ...

- **[MBX Biosciences shares Phase 2 hypoparathyroidism data as it seeks to compete with Ascendis, AstraZeneca](https://endpoints.news/mbx-biosciences-shares-phase-2-hypoparathyroidism-data-as-it-seeks-to-compete-with-ascendis-astrazeneca/)**  
  _Mon, 22 Sep 2025 11:00:01 +0000_  
  MBX Biosciences said Monday that its experimental drug canvuparatide cleared the bar in a Phase 2 trial in a rare endocrine disorder called hypoparathyroidism.

 The once-weekly drug helped 63% of patients ...

- **[Pfizer goes full speed ahead on obesity with $4.9B acquisition of Metsera](https://endpoints.news/pfizer-goes-full-speed-ahead-on-obesity-with-4-9b-acquisition-of-metsera/)**  
  _Mon, 22 Sep 2025 10:49:36 +0000_  
  After looking like a down-and-out player in obesity, Pfizer is making the flashiest acquisition yet by a large pharma in the weight loss field.

 On Monday, Pfizer announced it would buy ...

- **[Roche declares Phase 3 win for SERD in broad breast cancer population that eluded competitors](https://endpoints.news/roche-declares-phase-3-win-for-serd-in-broad-breast-cancer-population-that-eluded-competitors/)**  
  _Mon, 22 Sep 2025 10:29:20 +0000_  
  Roche’s estrogen receptor-targeting pill beat standard of care in a Phase 3 breast cancer trial, the company said Monday. However, one key question remains: Out of all the patients in the ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/we-have-will-roche-unveils-strategy-become-top-3-obesity-company" hreflang="en">'We have the will': Roche unveils strategy to become 'top 3' obesity company</a>](https://www.fiercebiotech.com/biotech/we-have-will-roche-unveils-strategy-become-top-3-obesity-company)**  
  _Sep 22, 2025 7:33am_  
  Roche has set its sights on becoming a “top three” obesity company, according to the pharma’s long-awaited strategy for cracking the weight loss market.

- **[<a href="https://www.fiercebiotech.com/biotech/sanofis-troubled-ms-hopeful-tolebrutinib-hit-fda-delay" hreflang="en">Sanofi's troubled MS hopeful tolebrutinib hit by FDA delay </a>](https://www.fiercebiotech.com/biotech/sanofis-troubled-ms-hopeful-tolebrutinib-hit-fda-delay)**  
  _Sep 22, 2025 2:39am_  
  Sanofi’s long and winding path to get its investigational multiple sclerosis drug over the regulatory finish line has taken another turn with the FDA's move to delay its approval decision on the candidate by three months.

- **[<a href="https://www.fiercebiotech.com/biotech/pfizer-inks-49b-metsera-buyout-beef-obesity-pipeline-following-internal-setbacks" hreflang="en">Pfizer inks $4.9B upfront Metsera buyout to beef up obesity pipeline following internal setbacks</a>](https://www.fiercebiotech.com/biotech/pfizer-inks-49b-metsera-buyout-beef-obesity-pipeline-following-internal-setbacks)**  
  _Sep 22, 2025 7:48am_  
  Pfizer has thrown money at its obesity R&D problem. Having seen its internal assets flounder, the Big Pharma has struck a deal to buy Metsera for an initial $4.9 billion to secure a pipeline of injectable and oral drug candidates.

- **[<a href="https://www.fiercebiotech.com/biotech/roche-reports-phase-3-breast-cancer-victory-starting-key-period-oral-serd-win" hreflang="en">Roche reports phase 3 breast cancer victory, starting key period for oral SERD with a win</a>](https://www.fiercebiotech.com/biotech/roche-reports-phase-3-breast-cancer-victory-starting-key-period-oral-serd-win)**  
  _Sep 22, 2025 7:15am_  
  Roche has reported a phase 3 win for its oral selective estrogen receptor degrader, bouncing back from an earlier setback to deliver data that could support filings for approval in breast cancer.

- **[<a href="https://www.fiercebiotech.com/biotech/genfit-ends-liver-failure-program-after-seeing-adverse-event-phase-2-trial" hreflang="en">Genfit ends liver failure program after seeing adverse event in phase 2 trial</a>](https://www.fiercebiotech.com/biotech/genfit-ends-liver-failure-program-after-seeing-adverse-event-phase-2-trial)**  
  _Sep 22, 2025 5:15am_  
  Genfit has stopped development of VS-01 in acute-on-chronic liver failure after a patient suffered a serious adverse event in a phase 2 trial.

- **[<a href="https://www.fiercebiotech.com/biotech/two-years-after-carmot-buyout-whats-next-roches-expensive-obesity-pipeline" hreflang="en">2 years after Carmot buyout, what’s next for Roche’s expensive obesity pipeline?</a>](https://www.fiercebiotech.com/biotech/two-years-after-carmot-buyout-whats-next-roches-expensive-obesity-pipeline)**  
  _Sep 19, 2025 9:42am_  
  It’s been less than two years since Roche dove into the obesity space with its $2.7 billion acquisition of Carmot Therapeutics—but a lot has changed since then.


## Regeneron Press Releases

- **[Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion](https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-treat-chronic-spontaneous-urticaria-csu)**  
  _Mon, 22 Sep 2025 00:29:00 -0400_  
  Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over a decade indicated for CSU in the European Union (EU) TARRYTOWN, N.Y.


## arXiv q-bio

- **[Assessing metadata privacy in neuroimaging](https://arxiv.org/abs/2509.15278)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15278v1 Announce Type: new 
Abstract: The ethical and legal imperative to share research data without causing harm requires careful attention to privacy risks. While mounting evidence demonstrates that data sharing benefits science, legitimate concerns persist regarding the potential leakage of personal inf…

- **[Epidemic amplification by correlated superspreading](https://arxiv.org/abs/2509.15338)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15338v1 Announce Type: new 
Abstract: Infectious pathogens often propagate by superspreading, which focusses onward transmission on disproportionately few infected individuals. At the same time, infector-infectee pairs tend to have more similar transmission potentials than expected by chance, as risk factor…

- **[Incorporating Visual Cortical Lateral Connection Properties into CNN: Recurrent Activation and Excitatory-Inhibitory Separation](https://arxiv.org/abs/2509.15460)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15460v1 Announce Type: new 
Abstract: The original Convolutional Neural Networks (CNNs) and their modern updates such as the ResNet are heavily inspired by the mammalian visual system. These models include afferent connections (retina and LGN to the visual cortex) and long-range projections (connections acr…

- **[siDPT: siRNA Efficacy Prediction via Debiased Preference-Pair Transformer](https://arxiv.org/abs/2509.15664)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15664v1 Announce Type: new 
Abstract: Small interfering RNA (siRNA) is a short double-stranded RNA molecule (about 21-23 nucleotides) with the potential to cure diseases by silencing the function of target genes. Due to its well-understood mechanism, many siRNA-based drugs have been evaluated in clinical tr…

- **[A Visual Discrete Event-based Simulator for Protection of Plants against Herbivores Employed as Computational Optimization Game](https://arxiv.org/abs/2509.15787)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15787v1 Announce Type: new 
Abstract: Plants come with sophisticated strategies to survive within a highly competing environment. In addition, they need to resist frequent attacks from a variety of herbivores acting alone, in small groups, or in swarms. Since the amount of energy a plant might invest in def…

- **[Overcoming Output Dimension Collapse: How Sparsity Enables Zero-shot Brain-to-Image Reconstruction at Small Data Scales](https://arxiv.org/abs/2509.15832)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15832v1 Announce Type: new 
Abstract: Advances in brain-to-image reconstruction are enabling us to externalize the subjective visual experiences encoded in the brain as images. Achieving such reconstruction with limited training data requires generalization beyond the training set, a task known as zero-shot…

- **[Changes in Liver Fibrosis in Patients with Chronic Hepatitis B Treated with Pegylated Interferon Combined with Oral Antiviral Agents: A 48-Week Observation from a Prospective Cohort Study](https://arxiv.org/abs/2509.15854)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15854v1 Announce Type: new 
Abstract: Background and Aims: Pegylated interferon (PEG-IFN) combined with oral antiviral agents is currently the most widely used and highly effective treatment regimen for chronic hepatitis B virus (HBV) infection. While effectively suppressing HBV replication, its impact on l…

- **[The evolution of asymmetrical regulation of physiology is central to aging](https://arxiv.org/abs/2509.15911)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15911v1 Announce Type: new 
Abstract: The evolutionary biology of aging is fundamental to understanding the mechanisms of aging and how to develop anti-aging treatments. Thus far most evolutionary theory concerns the genetics of aging with limited physiological integration. Here we present an intuitive evol…

- **[A Hypothesis-First Framework for Mechanistic Model Evaluation and Selection in Neuroimaging](https://arxiv.org/abs/2509.16070)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.16070v1 Announce Type: new 
Abstract: Neuroimaging provides rich measurements of brain structure and neural activity, but turning these data into mechanistic insight remains difficult. Statistical models quantify associations without much considerations for how they arise, whereas bio-realistic models direc…

- **[A Unified and Predictive Measure of Functional Diversity](https://arxiv.org/abs/2509.16133)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.16133v1 Announce Type: new 
Abstract: Despite the critical role of functional diversity (FD) in understanding ecological systems and processes, its robust quantification remains a significant challenge. A long-held view in the field is that it is not possible to capture its three facets -- functional richne…

- **[Kuramoto Orientation Diffusion Models](https://arxiv.org/abs/2509.15328)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15328v1 Announce Type: cross 
Abstract: Orientation-rich images, such as fingerprints and textures, often exhibit coherent angular directional patterns that are challenging to model using standard generative approaches based on isotropic Euclidean diffusion. Motivated by the role of phase synchronization in…

- **[Random Matrix Theory-guided sparse PCA for single-cell RNA-seq data](https://arxiv.org/abs/2509.15429)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15429v1 Announce Type: cross 
Abstract: Single-cell RNA-seq provides detailed molecular snapshots of individual cells but is notoriously noisy. Variability stems from biological differences, PCR amplification bias, limited sequencing depth, and low capture efficiency, making it challenging to adapt computat…

- **[Hybrid Lie semi-group and cascade structures for the generalized Gaussian derivative model for visual receptive fields](https://arxiv.org/abs/2509.15748)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15748v1 Announce Type: cross 
Abstract: Because of the variabilities of real-world image structures under the natural image transformations that arise when observing similar objects or spatio-temporal events under different viewing conditions, the receptive field responses computed in the earliest layers of…

- **[Monte Carlo Tree Diffusion with Multiple Experts for Protein Design](https://arxiv.org/abs/2509.15796)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.15796v1 Announce Type: cross 
Abstract: The goal of protein design is to generate amino acid sequences that fold into functional structures with desired properties. Prior methods combining autoregressive language models with Monte Carlo Tree Search (MCTS) struggle with long-range dependencies and suffer fro…

- **[Lateral oscillation and body compliance help snakes and snake robots stably traverse large, smooth obstacles](https://arxiv.org/abs/2003.13733)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2003.13733v2 Announce Type: replace-cross 
Abstract: Snakes can move through almost any terrain. Similarly, snake robots hold the promise as a versatile platform to traverse complex environments like earthquake rubble. Unlike snake locomotion on flat surfaces which is inherently stable, when snakes traverse comp…

- **[An energy landscape approach to locomotor transitions in complex 3D terrain](https://arxiv.org/abs/2006.12717)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2006.12717v2 Announce Type: replace-cross 
Abstract: Effective locomotion in nature happens by transitioning across multiple modes (e.g., walk, run, climb). Despite this, far more mechanistic understanding of terrestrial locomotion has been on how to generate and stabilize around near-steady-state movement in a…

- **[Coordinated appendages accumulate more energy to self-right on the ground](https://arxiv.org/abs/2008.08981)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2008.08981v2 Announce Type: replace-cross 
Abstract: Animals and robots must right themselves after flipping over on the ground. The discoid cockroach pushes its wings against the ground in an attempt to dynamically self-right by a somersault. However, because this maneuver is strenuous, the animal often fails t…

- **[Multi-modal Adaptive Estimation for Temporal Respiratory Disease Outbreak](https://arxiv.org/abs/2509.08578)**  
  _Mon, 22 Sep 2025 00:00:00 -0400_  
  arXiv:2509.08578v3 Announce Type: replace-cross 
Abstract: Timely and robust influenza incidence forecasting is critical for public health decision-making. This paper presents MAESTRO (Multi-modal Adaptive Estimation for Temporal Respiratory Disease Outbreak), a novel, unified framework that synergistically integrates…
